# MHRA

Type: organization

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/mhra-organization
Canonical HTML page: https://gethealthbrief.com/entity/mhra-organization

## Timeline

- **2026-06-15**: Committee Review — Expected date for health select committee to begin detailed scrutiny of the bill.
- **2026-04-01**: Expected Appeal Date — Final appraisal committee meeting to review new evidence and potential Managed Access Agreements.
- **2026-03-06**: National Campaign Launch — Bereaved family and patient advocates launch a coordinated media campaign imploring the NHS to reconsider.
- **2026-02-27**: Draft Law Unveiled — The Rare Cancers Law is formally introduced as a draft to Parliament.
- **2026-02-19**: Official Reporting — MHRA and GOV.UK release data confirming the surge in neurotech and AI testing activity.
- **2026-01-15**: NICE Initial Review — NICE issues a preliminary recommendation against routine funding based on cost-effectiveness.
- **2025-12-31**: Record Achievement — Total CINs for the year reach 137, a new historical high for the agency.
- **2025-11-12**: MHRA Approval — The drug receives safety and efficacy licensing for use in the UK market.
- **2025-09-05**: Policy Consultation — UK Government opens consultation on rare disease frameworks.
- **2025-06-15**: IDAP Expansion — The MHRA expands the Innovative Devices Access Pathway to include more AI-driven startups.
- **2024-12-31**: Baseline Growth — UK concludes 2024 with 104 clinical investigation notifications.
- **2024-11-12**: Advocacy Surge — Brain tumor charities increase lobbying efforts for legislative reform.

## Recent coverage (5 stories)

### Wegovy Pill Approved With 87% of Patients Losing ≥5% Body Weight
2026-06-15 08:00:50 · Sentiment: Bullish · Impact: 7/10 · Sources: 3

The MHRA approval of Novo Nordisk's oral semaglutide for obesity triggers a private prescribing boom, with pharmacies reporting 100,000 on waiting lists. The pill shows 87% of adherent patients in trials lost at least 5% body weight, with one in three losing 20%+. NHS discussions are under way, but no coverage timeline is set, leaving patients to navigate private costs.
Full story: https://gethealthbrief.com/story/wegovy-pill-mhra-approval-87-percent-weight-loss

### First Daily GLP-1 Pill Approved: Wegovy Oral Achieves 17% Weight Loss in Trial
2026-06-11 16:43:14 · Sentiment: Bullish · Impact: 8/10 · Sources: 3

The MHRA’s landmark approval of oral semaglutide introduces a needle-free GLP-1 option for obesity, backed by a 17% weight-loss result in adherent patients. Healthcare providers must now navigate private-only access and patient education around strict dosing protocols.
Full story: https://gethealthbrief.com/story/wegovy-pill-uk-approval-oral-semaglutide-17-percent-weight-loss

### NHS Faces Mounting Pressure to Approve High-Efficacy Cancer Therapies
2026-03-06 01:31:00 · Sentiment: Bearish · Impact: 7/10 · Sources: 11

A bereaved family's national campaign has ignited a fierce debate over the NHS's refusal to fund a new treatment for aggressive cancer despite evidence of significant tumor shrinkage. The case underscores the growing tension between rapid pharmaceutical innovation and the UK's rigid cost-effectiveness appraisal frameworks.
Full story: https://gethealthbrief.com/story/nhs-regulatory-pressure-aggressive-cancer-treatment

### UK Draft Rare Cancers Law Targets Incurable Brain Tumor Treatment Gaps
2026-02-27 01:23:41 · Sentiment: Bullish · Impact: 7/10 · Sources: 4

The UK government is advancing a draft Rare Cancers Law designed to fast-track treatments and research for patients with incurable brain tumors. This legislative push aims to dismantle bureaucratic barriers that have historically hindered drug development and clinical trial access for rare oncological conditions.
Full story: https://gethealthbrief.com/story/uk-rare-cancers-law-brain-tumors

### UK Medical Device Testing Hits Record High as MHRA Accelerates AI and Neurotech
2026-02-19 12:17:51 · Sentiment: Bullish · Impact: 7/10 · Sources: 2

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) reported a record 137 clinical investigation notifications in 2025, a 32% increase over the previous year. This surge is driven by a strategic regulatory pivot toward AI-driven diagnostics and brain-computer interfaces, signaling the UK's intent to lead in high-risk medical innovation.
Full story: https://gethealthbrief.com/story/uk-mhra-medical-device-testing-record-high-ai-neurotech

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.